Global Cancer Biomarker Testing Market - 2026-2033
Global Cancer Biomarker Testing Market reached US$ 37.58 Billion in 2025 and is expected to reach US$ 96.53 billion by 2033, growing with a CAGR of 12.60% during the forecast period 2026-2033.
The Global Cancer Biomarker Testing Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Global Cancer Biomarker Testing Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Biomarker Type
By End-User
Both primary and secondary data sources have been used in the global Global Cancer Biomarker Testing Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Global Cancer Biomarker Testing Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Global Cancer Biomarker Testing Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Biomarker Type
- Genetic Biomarkers*
- Protein Biomarkers
- Others
- Omics Technologies*
- Imaging Technologies
- Immunoassays
- Next-Generation Sequencing (NGS)
- PCR-based Techniques
- Others
- Instruments*
- Consumables
- Software
- Diagnostics*
- Drug Discovery and Development
- Therapy Prediction and Monitoring
- Personalized and Precision Medicine
- Others
- Global Cancer Biomarker Testing Market, By Cancer Type
- Breast Cancer*
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Cervical Cancer
- Liver Cancer
- Melanoma
- Blood Cancers
By End-User
- Hospitals *
- Diagnostic Laboratories
- Biopharmaceutical and Biotechnology Companies
- Others
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Global Cancer Biomarker Testing Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Biomarker Type
2.4. Snippet by Technology
2.5. Snippet by Product Type
2.6. Snippet by Application
2.7. Snippet by Cancer Type
2.8. Snippet by End-User
2.9. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Emergence of Multi-Omics and AI-Driven Diagnostics
3.1.1.2. Shift Toward Personalized and Precision Medicine
3.1.1.3. Rising Global Cancer Prevalence
3.1.2. Restraints
3.1.2.1. High Cost of Biomarker Tests and Drug Development
3.1.2.2. Stringent Regulatory and Reimbursement Challenges
3.1.2.3. Data Privacy and Management Concerns
3.1.3. Opportunity
3.1.3.1. Development of Novel Biomarkers
3.1.3.2. Integration with Digital Health and Telemedicine
3.1.3.3. Expansion of Non-Invasive Testing
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with the largest-selling Brand
4.1.3. Market leaders with established Product
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.11. Pricing Analysis and Price Dynamics
5. GLOBAL CANCER BIOMARKER TESTING MARKET, BY BIOMARKER TYPE
5.1. Introduction
5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
5.1.2. Market Attractiveness Index By Biomarker Type
5.2. Genetic Biomarkers*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Protein Biomarkers
5.4. Others
6. GLOBAL CANCER BIOMARKER TESTING MARKET, BY TECHNOLOGY
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
6.1.2. Market Attractiveness Index By Technology
6.2. Omics Technologies*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Imaging Technologies
6.4. Immunoassays
6.5. Next-Generation Sequencing (NGS)
6.6. PCR-based Techniques
6.7. Others
7. GLOBAL CANCER BIOMARKER TESTING MARKET, BY PRODUCT TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index By Product Type
7.2. Instruments*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Consumables
7.4. Software
8. GLOBAL CANCER BIOMARKER TESTING MARKET, BY APPLICATION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index By Application
8.2. Diagnostics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Drug Discovery and Development
8.4. Therapy Prediction and Monitoring
8.5. Personalized and Precision Medicine
8.6. Others
8.7. Global Cancer Biomarker Testing Market, By Cancer Type
8.8. Introduction
8.8.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.8.2. Market Attractiveness Index By Cancer Type
8.9. Breast Cancer*
8.9.1. Introduction
8.9.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.10. Lung Cancer
8.11. Colorectal Cancer
8.12. Prostate Cancer
8.13. Cervical Cancer
8.14. Liver Cancer
8.15. Melanoma
8.16. Blood Cancers
8.17. Others
9. GLOBAL CANCER BIOMARKER TESTING MARKET, BY END-USER
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Diagnostic Laboratories
9.4. Biopharmaceutical and Biotechnology Companies
9.5. Others
10. GLOBAL CANCER BIOMARKER TESTING MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.9.1. U.S.
10.2.9.2. Canada
10.2.9.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.9.1. Germany
10.3.9.2. U.K.
10.3.9.3. France
10.3.9.4. Spain
10.3.9.5. Italy
10.3.9.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.9.1. Brazil
10.4.9.2. Argentina
10.4.9.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.9.1. China
10.5.9.2. India
10.5.9.3. Japan
10.5.9.4. South Korea
10.5.9.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
11.1. Competitive Overview and Key Market Players
11.2. Market Share Analysis and Positioning Matrix
11.3. Strategic Partnerships, Mergers & Acquisitions
11.4. Key Developments in Product Portfolios and Innovations
11.5. Company Benchmarking
12. COMPANY PROFILES
12.1. Illumina, Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio
12.1.2.1. Product Description
12.1.2.2. Product Key Performance Indicators (KPIs)
12.1.2.3. Historic and Forecasted Product Sales
12.1.2.4. Product Sales Volume
12.1.3. Financial Overview
12.1.3.1. Company Revenue
12.1.3.2. Geographical Revenue Shares
12.1.3.3. Revenue Forecasts
12.1.4. Key Developments
12.1.4.1. Mergers & Acquisitions
12.1.4.2. Key Product Development Activities
12.1.4.3. Regulatory Approvals, etc.
12.1.5. SWOT Analysis
12.2. F. Hoffmann-La Roche Ltd
12.3. Thermo Fisher Scientific Inc.
12.4. Abbott
12.5. QIAGEN
12.6. Siemens Healthineers AG
12.7. Bio-Rad Laboratories, Inc
12.8. Agilent Technologies
12.9. BioM?rieux
12.10. Foundation Medicine, Inc. (LIST NOT EXHAUSTIVE)
13. ASSUMPTIONS AND RESEARCH METHODOLOGY
13.1. Data Collection Methods
13.2. Data Triangulation
13.3. Forecasting Techniques
13.4. Data Verification and Validation
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Biomarker Type
2.4. Snippet by Technology
2.5. Snippet by Product Type
2.6. Snippet by Application
2.7. Snippet by Cancer Type
2.8. Snippet by End-User
2.9. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Emergence of Multi-Omics and AI-Driven Diagnostics
3.1.1.2. Shift Toward Personalized and Precision Medicine
3.1.1.3. Rising Global Cancer Prevalence
3.1.2. Restraints
3.1.2.1. High Cost of Biomarker Tests and Drug Development
3.1.2.2. Stringent Regulatory and Reimbursement Challenges
3.1.2.3. Data Privacy and Management Concerns
3.1.3. Opportunity
3.1.3.1. Development of Novel Biomarkers
3.1.3.2. Integration with Digital Health and Telemedicine
3.1.3.3. Expansion of Non-Invasive Testing
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with the largest-selling Brand
4.1.3. Market leaders with established Product
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.11. Pricing Analysis and Price Dynamics
5. GLOBAL CANCER BIOMARKER TESTING MARKET, BY BIOMARKER TYPE
5.1. Introduction
5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
5.1.2. Market Attractiveness Index By Biomarker Type
5.2. Genetic Biomarkers*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Protein Biomarkers
5.4. Others
6. GLOBAL CANCER BIOMARKER TESTING MARKET, BY TECHNOLOGY
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
6.1.2. Market Attractiveness Index By Technology
6.2. Omics Technologies*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Imaging Technologies
6.4. Immunoassays
6.5. Next-Generation Sequencing (NGS)
6.6. PCR-based Techniques
6.7. Others
7. GLOBAL CANCER BIOMARKER TESTING MARKET, BY PRODUCT TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index By Product Type
7.2. Instruments*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Consumables
7.4. Software
8. GLOBAL CANCER BIOMARKER TESTING MARKET, BY APPLICATION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index By Application
8.2. Diagnostics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Drug Discovery and Development
8.4. Therapy Prediction and Monitoring
8.5. Personalized and Precision Medicine
8.6. Others
8.7. Global Cancer Biomarker Testing Market, By Cancer Type
8.8. Introduction
8.8.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.8.2. Market Attractiveness Index By Cancer Type
8.9. Breast Cancer*
8.9.1. Introduction
8.9.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.10. Lung Cancer
8.11. Colorectal Cancer
8.12. Prostate Cancer
8.13. Cervical Cancer
8.14. Liver Cancer
8.15. Melanoma
8.16. Blood Cancers
8.17. Others
9. GLOBAL CANCER BIOMARKER TESTING MARKET, BY END-USER
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Diagnostic Laboratories
9.4. Biopharmaceutical and Biotechnology Companies
9.5. Others
10. GLOBAL CANCER BIOMARKER TESTING MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.9.1. U.S.
10.2.9.2. Canada
10.2.9.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.9.1. Germany
10.3.9.2. U.K.
10.3.9.3. France
10.3.9.4. Spain
10.3.9.5. Italy
10.3.9.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.9.1. Brazil
10.4.9.2. Argentina
10.4.9.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.9.1. China
10.5.9.2. India
10.5.9.3. Japan
10.5.9.4. South Korea
10.5.9.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
11.1. Competitive Overview and Key Market Players
11.2. Market Share Analysis and Positioning Matrix
11.3. Strategic Partnerships, Mergers & Acquisitions
11.4. Key Developments in Product Portfolios and Innovations
11.5. Company Benchmarking
12. COMPANY PROFILES
12.1. Illumina, Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio
12.1.2.1. Product Description
12.1.2.2. Product Key Performance Indicators (KPIs)
12.1.2.3. Historic and Forecasted Product Sales
12.1.2.4. Product Sales Volume
12.1.3. Financial Overview
12.1.3.1. Company Revenue
12.1.3.2. Geographical Revenue Shares
12.1.3.3. Revenue Forecasts
12.1.4. Key Developments
12.1.4.1. Mergers & Acquisitions
12.1.4.2. Key Product Development Activities
12.1.4.3. Regulatory Approvals, etc.
12.1.5. SWOT Analysis
12.2. F. Hoffmann-La Roche Ltd
12.3. Thermo Fisher Scientific Inc.
12.4. Abbott
12.5. QIAGEN
12.6. Siemens Healthineers AG
12.7. Bio-Rad Laboratories, Inc
12.8. Agilent Technologies
12.9. BioM?rieux
12.10. Foundation Medicine, Inc. (LIST NOT EXHAUSTIVE)
13. ASSUMPTIONS AND RESEARCH METHODOLOGY
13.1. Data Collection Methods
13.2. Data Triangulation
13.3. Forecasting Techniques
13.4. Data Verification and Validation
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
